Concepedia

Publication | Open Access

Two randomized migraine studies of galcanezumab

DOIFull Paper Access

33

Citations

26

References

2019

Year

Janet H. Ford, David W. Ayer, Qi Zhang, Jeffrey N. Carter, Élizabeth Leroux, Vladimir Skljarevski, Sheena K. Aurora, Antje Tockhorn‐Heidenreich, Richard B. Lipton
Neurology

Abstract

This study provides Class II evidence that for patients with migraine, galcanezumab (120 mg or 240 mg) given once monthly improved functioning and reduced disability.

References

YearCitations

Page 1